IMPORTANT NOTICE FOR BOOSTRIX, CERVARIX AND HAVRIX - VACCINES ACCESS PROGRAM ONLY:

The GSK Vaccines Access Program has temporarily suspended enrollment of patients into our Program for Cervarix as of 9/15/2014.  This temporary suspension has been caused by a product supply issue that has been identified. This issue only affects the Cervarix package of 1, which is only available for the Vaccines Access Program. This shortage does not have any effect on the supply of Cervarix in the commercial market. We apologize for any inconvenience.

Effective 9/17/2014 Havrix is available again in the GSK Vaccines Access Program.

Effective 11/5/2014 Boostrix is available again in the GSK Vaccines Access Program

All updates on program status will be posted to this website.  Questions regarding the GSK Vaccines Access Program can be addressed by calling Program representatives at 1–877–VACC–911, M–F, 9:00am–7:00pm ET.

About the program

GSK Vaccines Access Program is a patient assistance program sponsored by GlaxoSmithKline that provides GlaxoSmithKline vaccines to adult applicants who meet eligibility requirements. This program does not constitute health insurance

There are three easy steps to providing free vaccine to eligible patients:

  1. Prior to enrolling patients, prescribers must register in the program.
  2. For patient enrollment, prescribers must fax the completed and signed application along with the applicant’s income documentation to 1-877-822-1555. To access the application in Spanish, click here. Once approved, the applicant will be eligible to receive vaccine for up to one year.
  3. Once enrolled, the patient can receive subsequent doses of vaccine by having the prescriber complete the Dose Authorization Request Form.
Click on "Learn more" to find out how the program works
GlaxoSmithKline

This website is funded and developed by GlaxoSmithKline.
This site is intended for US healthcare professionals only.
© 1997-2014 GlaxoSmithKline. All Rights Reserved.
Legal Notices | Privacy Statement | Medicine Savings | Contact Us